|Bid||0.6368 x 1200|
|Ask||0.6370 x 900|
|Day's Range||0.5700 - 0.6860|
|52 Week Range||0.4900 - 2.5800|
|Beta (3Y Monthly)||2.34|
|PE Ratio (TTM)||N/A|
|Earnings Date||Aug 7, 2017 - Aug 11, 2017|
|Forward Dividend & Yield||N/A (N/A)|
|1y Target Est||1.81|
The Gaithersburg, Maryland-based company said it had a loss of 13 cents per share. The results missed Wall Street expectations. The average estimate of five analysts surveyed by Zacks Investment Research ...
GAITHERSBURG, Md., March 18, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced its financial results and operational highlights for the fourth quarter and twelve months.
Biotech stocks had an upweek, with the release of clinical trial results and the positive broader market sentiment offering ample support. Here are some key catalysts that can move biotech stocks in the ...
CORAL GABLES, FL / ACCESSWIRE / March 13, 2019 / The healthcare stock market has managed to attract significant attention in the initial months of 2019 as a result of healthcare companies demonstrating to investors and consumers their commitment to the future of the industry. Premier Health Group (OTC:PHGRF) (CSE:PHGI), Novavax Inc (NVAX), Advaxis Inc (ADXS), and MannKind Corporation (MNKD) are 4 healthcare companies raising the bar on Wednesday. Premier Health Group (OTC:PHGRF) (CSE:PHGI) is a company determined to develop innovative approaches that combine human skill-based expertise with state-of-the-art technologies to offer to their patients the best possible treatment solutions and primary care.
CORAL GABLES, FL / ACCESSWIRE / March 12, 2019 / The healthcare stock market is comprised of innovative companies working diligently to design, manufacture, and commercialize state-of-the-art tech-driven solutions for the healthcare industry. It is the responsibility of healthcare companies to meet the oncoming challenges presented by infectious diseases and ailments, and so long as they can meet these requirements, the healthcare sector could generate market excitement. Premier Health Group (OTC:PHGRF) (CSE:PHGI), ENDRA Life Sciences Inc (NDRA), Novavax Inc (NVAX), and Aevi Genomic Medicine Inc (GNMX) are 4 healthcare companies raising the bar on Tuesday.
GAITHERSBURG, Md., March 11, 2019 -- Novavax, Inc. (Nasdaq: NVAX) today announced it will report its fourth quarter 2018 financial and operating results prior to U.S. financial.
The move to get patients out of doctors offices and hospitals quickly using virtual care and remote monitoring is underway. Technology is enabling the switch, and few sub-sectors have benefited more than remote cardiac care. Companies like Biotelemetry (BEAT) have grown by leaps and bounds in the last few years as their proprietary remote cardiac monitoring devices have gained traction.
At the end of the day, our health is our key priority, and it is the responsibility of the healthcare industry to meet the growing demands of consumers as more diseases are discovered. Interestingly enough, amid this responsibly lies the opportunity for healthcare companies to unlock lucrative potential and attract investors to the space. If companies in the healthcare sector continue to take creative approaches to design drug treatments and care solutions, this will, in turn, improve the lives of consumers, thus catalyzing significant investor interest in the sector.
Novavax (NVAX) is expected to provide updates on its lead vaccine candidate, Resvax when it reports fourth-quarter 2018 results.
As Kenny Rogers sang, you've got to know when to hold 'em and know when to fold 'em… and sometimes when not to play a hand at all.
Here's a roundup of top developments in the biotech space over the last 24 hours: Scaling The Peaks (Biotech stocks hitting 52-week highs on Feb. 28) Amphastar Pharmaceuticals Inc (NASDAQ: AMPH ) Abbott ...
Why Novavax Is Tanking TodayShare price movementsToday, Novavax (NVAX) is trading close to $0.70, which is about 67.13% lower than its previous closing price. The company has a market capitalization of $806.95 million.Today, the company issued a
Novavax news concerning the results from the recent trail of its drug ResVax has NVAX stock falling on Thursday.Source: Phalinn Ooi via FlickrAccording to Novavax (NASDAQ:NVAX) the Phase 3 clinical trial for ResVax was unable to meet its primary endpoint. The goal was for the vaccine to prevent respiratory syncytial virus (RSV) lower respiratory tract infection (LRTI) by a medically significant degree.The primary results from the Phase 3 Novavax news only has it being effective 39% against medically significant RSV LRTI. One of the secondary results have it being 44% effective against RSV LRTI hospitalizations. The other has it being 48% effective against RSV LRTI with severe hypoxemia.InvestorPlace - Stock Market News, Stock Advice & Trading TipsResVax is an aluminum adjuvanted respiratory syncytial virus fusion protein recombinant nanoparticle vaccine. This vaccine is administered to the mother in hopes of passing its effects on to her children. * 9 Best Stocks to Buy on U.S.-China Trade Optimism "Our next steps include meeting with U.S. and European regulators to review these data and to discuss the path forward for licensure," Stanley Erck, President and CEO of Novavax, said in a statement. "We wish to acknowledge and thank the investigators, the Novavax team and the many mothers and their families around the world that participated in this historic trial, bringing the world one step closer to an RSV vaccine."The poor results from the Phase 3 clinical trial for ResVax was incredibly bad Novavax news for NVX stock. NVX stock was down 66% as of noon Thursday. More From InvestorPlace * 2 Toxic Pot Stocks You Should Avoid * The 5 STARS Stocks That Continue to Define the Future * 7 of the Best ETFs to Buy for a Rock-Solid Portfolio * 5 Real Estate Stocks to Buy for Dividend Income As of this writing, William White did not hold a position in any of the aforementioned securities.Compare Brokers The post Novavax News: Why NVAX Stock Is Plunging Today appeared first on InvestorPlace.
Novavax said the global Phase 3 trial dubbed PREPARE that evaluated ResVax did not meet the primary endpoint of prevention of medically significant respiratory syncytial virus, or RSV, and lower respiratory tract infection, or LTRI. ResVax is an aluminum adjuvanted RSV fusion protein recombinant nanoparticle vaccine. It is being developed for protecting infants through maternal immunization against RSV disease.